Strs Ohio Invests $47,000 in ZimVie Inc. (NASDAQ:ZIMV)

Strs Ohio purchased a new position in shares of ZimVie Inc. (NASDAQ:ZIMV – Get Rating) during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 4,800 shares of the company’s stock, valued at approximately $47,000.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Allspring Global Investments Holdings LLC acquired a new position in ZimVie during the third quarter worth about $71,000. Louisiana State Employees Retirement System acquired a new position in ZimVie during the third quarter worth about $99,000. Raymond James & Associates acquired a new position in ZimVie during the third quarter worth about $110,000. Mackenzie Financial Corp acquired a new position in ZimVie during the third quarter worth about $135,000. Finally, State of Alaska Department of Revenue acquired a new position in ZimVie during the third quarter worth about $142,000. 74.29% of the stock is currently owned by institutional investors and hedge funds.

ZimVie Trading Up 1.9 %

Shares of NASDAQ ZIMV opened at $8.46 on Monday. ZimVie Inc. has a 12-month low of $6.67 and a 12-month high of $50.40. The company has a quick ratio of 1.48, a current ratio of 2.51 and a debt-to-equity ratio of 0.76. The firm’s 50-day moving average is $9.01 and its two-hundred day moving average is $11.98.

ZimVie (NASDAQ:ZIMV – Get Rating) last announced its quarterly earnings data on Wednesday, November 9th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.27 by $0.22. The business had revenue of $214.58 million for the quarter, compared to the consensus estimate of $214.83 million. ZimVie had a negative net margin of 9.96% and a negative return on equity of 2.75%. Research analysts anticipate that ZimVie Inc. will post 1.95 EPS for the current year.

Analyst Ratings Changes

Separately, Barclays initiated coverage on shares of ZimVie in a research report on Wednesday, December 21st. They set an “underweight” rating and a $9.00 target price on the stock.

ZimVie Profile

(Get Rating)

ZimVie Inc, a medical technology company, develops, manufactures, and delivers a portfolio of products and solutions designed to treat a range of spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It offers dental implant systems, prosthetic and abutment products, surgical instrumentation, and kits; bone grafts, barrier membranes, allografts, and collagen wound care products; intraoral scanners; and virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and patient-specific restorative components and intra-oral scanners, as well as spinal fusion implants and instrumentation for various spinal procedures, biologics, and bone healing technologies.